Brandehoff N., Benjamin J. M., Balde C., Chippaux Jean-Philippe. (2020). Ketamine for pain control of snake envenomation in Guinea : a case series. Toxicon, 187, p. 82-85. ISSN 0041-0101.
Titre du document
Ketamine for pain control of snake envenomation in Guinea : a case series
Brandehoff N., Benjamin J. M., Balde C., Chippaux Jean-Philippe
Source
Toxicon, 2020,
187, p. 82-85 ISSN 0041-0101
Snakebite envenomation is a global health crisis and is classified as a Category A neglected tropical disease by the World Health Organization (WHO). Snakebite envenomations account for a significant amount of morbidity and morbidity in tropical and subtropical regions. Recently, publications have illustrated the potential for snake envenomations causing post-traumatic stress disorder (PTSD) in a significant number of patients. Ketamine is on the WHO's list of essential medications and is used for a variety of pharmacologic applications including anesthesia and acute pain management. To date it has not been assessed for pain control in snakebite envenomations. Twelve patients who presented with severe pain secondary to Bitis, Causus, and Atractaspis envenomations were treated with low-dose intravenous ketamine. The patients included 7 males and 5 females with a median age of 37.5 (range 14-64) and a median presentation time of 5.75 h (range 5 min-96 h) after the initial bite occurred. Ten envenomations were presumed to have been caused by Bitis species resulting in extensive swelling and blistering of the affected extremities. One envenomation was presumedC. maculatus causing local swelling and pain. One envenomation was a presumed Atractaspis species causing significant local pain with minimal swelling. All patients expressed having significant pain but could not express the degree of their pain using an analogue pain scale. An initial median dose of 5 mg of ketamine (range 2.5-15 mg) was administered intravenously for pain control. Every patient expressed decreased pain and felt more comfortable within 1 min after administration of ketamine. Nine of the twelve patients only required a single dose. There were no adverse side effects. Ketamine appears to be an effective means of pain control for those suffering from painful envenomations. With minimal risk of significant side effects at acute pain management doses and the average cost per effective dose averaging between US0.03-0.06, this may provide a cheap, safe, and effective solution for Subsaharan Africa and other resource-limited settings. Controlled studies need to be done to critically assess our observations.
Plan de classement
Santé : généralités [050]
;
Sciences du monde animal [080]
Description Géographique
AFRIQUE SUBSAHARIENNE ; AFRQIUE DE L'OUEST ; GUINEE
